You are here: Home: BCU 9 | 2005: Breast Cancer Journal Club Notes


Oral Presentation. 2005 Proceedings of the American Society of Clinical Oncology Meeting, Orlando, Florida. No abstract available


  • Evaluate the addition of the anti-VEGF bevacizumab to paclitaxel as first-line therapy in patients with metastatic breast cancer

Patients and methods

  • 715 patients without prior chemotherapy for metastatic breast cancer enrolled
    – 350 patients received paclitaxel 90 mg/m2 qwk
    – 365 patients received paclitaxel + bevacizumab 10 mg/kg q2wk
  • HER2-positive only if prior treatment with or contraindication to trastuzumab
  • Adjuvant taxane only if disease-free interval >12 months
  • No therapeutic anticoagulation, no CNS metastases Results



Burstein HJ et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: A randomized phase II study. San Antonio Breast Cancer Symposium 2005;Abstract 4.

Cobleigh MA et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30(5 Suppl 16):117-24. Abstract

Drevs J et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004;24(3a):1759-63. Abstract

Hampton T. Monoclonal antibody therapies shine in breast cancer clinical trials. JAMA 2005;293(24):2985-9. No abstract available

Hudis CA. Clinical implications of antiangiogenic therapies. Oncology (Williston Park) 2005;19(4 Suppl 3):26-31. Abstract

Ignoffo RJ. Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm 2004;61(21 Suppl 5):21-6. Abstract

Martel CL et al. Incidence of bevacizumab (BE) related toxicities: Association of hypertension (HTN) and proteinuria (PTN), a BE toxicity syndrome (BETS). Proc ASCO 2005;Abstract 8062.

Miller KD. Recent translational research: Antiangiogenic therapy for breast cancer — Where do we stand? Breast Cancer Res 2004;6(3):128-32. Abstract

Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). San Antonio Breast Cancer Symposium 2005;Abstract 3.

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract

Miller KD, Dul CL. Breast cancer: The role of angiogenesis and antiangiogenic therapy. Hematol Oncol Clin North Am 2004;18(5):1071-86, ix. Abstract

Morabito A et al. Antiangiogenic strategies, compounds, and early clinical results in breast cancer. Crit Rev Oncol Hematol 2004;49(2):91-107. Abstract

Moses MA et al. A role for antiangiogenic therapy in breast cancer. Curr Oncol Rep 2004;6(1):42-8. Abstract

Ramaswamy B, Shapiro CL. Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancer. Clin Breast Cancer 2003;4(4):292-4. No abstract available

Rhee J, Hoff PM. Angiogenesis inhibitors in the treatment of cancer. Expert Opin Pharmacother 2005;6(10):1701-11. Abstract

Rugo HS. Bevacizumab in the treatment of breast cancer: Rationale and current data. Oncologist 2004;9(Suppl 1):43-9. Abstract

Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005;23(8):1782-90. No abstract available

Skillings JR et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. Proc ASCO 2005;Abstract 3019.

Traina TA et al. A feasibility study of an aromatase inhibitor (AI), letrozole (L) and the antibody to vascular endothelial growth factor (VEGF), bevacizumab (B), in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). Proc ASCO 2005;Abstract 796.



Editor’s Note:
Cheetos and raisins for dinner: The curse of Wilma and why a public sector that can’t figure out a way to get electricity to gas stations seems unlikely to
be victorious in the “war on cancer”
Harold J Burstein, MD, PhD
- Select publications
Charles L Vogel, MD
- Select publications
Eleftherios P Mamounas, MD, MPH
- Select publications
Journal Club

Breast Cancer Journal Club Notes

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Trastuzumab After Adjuvant Chemotherapy in HER2-Positive Breast Cancer

E2100: A Randomized Phase III Trial of Paclitaxel versus Paclitaxel Plus Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer

Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer (ABC) in Older Women

Fulvestrant versus Anastrozole for the Treatment of Advanced
Breast Carcinoma: A Prospectively Planned Combined Survival
Analysis of Two Multicenter Trials

Patterns of Care in Medical Oncology: A Case Survey Comparing Practices of Breast Cancer Investigators and General Oncologists — Section A: Adjuvant Endocrine Therapy


CME Information
Faculty Disclosures
Editor's Office